Profil
Daniel-Adriano Silva was the founder who started Neoleukin Therapeutics, Inc. in 2003, where he held the title of Vice President-Research until 2021.
He obtained an undergraduate degree from Universidad Nacional Autónoma de México.
Anciens postes connus de Daniel-Adriano Silva
| Sociétés | Poste | Fin |
|---|---|---|
| NEUROGENE INC. | Founder | 01/03/2021 |
Formation de Daniel-Adriano Silva
| Universidad Nacional Autónoma de México | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
